Wall Street analysts for probably the most half don’t see Salesforce inventory paying off soon after the cloud firm issued disappointing income steerage for its present quarter. Investors despatched Salesforce inventory decrease after the corporate informed traders to count on third-quarter income beneath what analysts had estimated. Salesforce predicted gross sales within the present quarter of between $10.24 billion and $10.29 billion, whereas consensus estimates had referred to as for income of $10.29 billion, in response to LSEG. In the second quarter that simply ended, Salesforce outcomes beat expectations on each the highest and backside traces, posting earnings of $2.91 per share on income of $10.24 billion, whereas analysts polled by LSEG had anticipated earnings of $2.78 on $10.14 billion in income. Shares of Salesforce had been down nearly 8% decrease in early buying and selling Thursday, one of many Dow Jones Industrial Average’s worst performers. The inventory has tumbled 29% this 12 months. CRM YTD mountain CRM YTD chart Despite the most recent steerage, Wall Street stays decidedly bullish. LSEG information exhibits that 41 analysts overlaying Salesforce charge it as a powerful purchase or purchase, whereas 11 give it a maintain and just one charges it a promote. Analyst reactions ranged from impartial to inspired by a possible turning level in Salesforce’s fortunes, pushed by alternatives in synthetic intelligence. Here’s what analysts at a few of Wall Street’s greatest banks are saying following Salesforce’s newest earnings report, from most bearish to most optimistic. Bernstein: Underperform score, $221 worth goal The financial institution’s worth goal implies the danger of 14% draw back forward, primarily based on Salesforce’s Wednesday closing worth of $256.45 per share. “We have been concerned that Salesforce is a mature business in a mature market and that expectations were running too high in general and especially as it relates to Agentforce. Plus, the possibility of large / expensive M & A remains a concern for us … However, we disagree with the broader concern that Gen-AI would destroy SaaS business model. We believe that platform vendors like Salesforce are positioned to deliver AI functionalities and monetize them. That said, size and timing remains uncertain.” UBS: Neutral, $260 The UBS worth goal implies shares will add simply 1% over the approaching 12 months. “For the second quarter in a row, Salesforce reaffirmed (didn’t raise) the FY26 total revs growth outlook of 8% despite the strong growth in the AI/Data segment (3% of revs) and positive commentary about the 2H pipeline and bookings momentum. This in our view speaks to a quite mature CRM software market and a reality that “front-office AI” investments are simply very early-stage. We’re content staying patient on the stock (we’re Neutral-rated) until we can more clearly see a path back to 10%+ growth.” Wells Fargo: Equal weight, $265 Analyst Michael Turrin’s goal would translate right into a achieve of three%. “Lack of a FY raise on a decent 2Q suggests less upside ROY than prev expected. Remain balanced until greater signs of a catalyst emerge, w/ Agentforce uptake proving slower than anticipated (ARR disclosure not given).” Citigroup: Neutral, $275 Citi’s new $275 worth goal, down from $295, corresponds to 7% upside. “We remain more cautious on CRM with partner feedback in F2Q suggesting an underwhelming demand picture: top-of-funnel activity is progressively weakening but there are still instances of ACV growth. Agentforce interest persists, though large-scale rollouts are rare, consistent with intra-Q takeaways at the Agentforce Boston event. We await more data points around wider rollouts and commercialization before turning constructive. We expect revenue growth to remain constrained in the HSD near-term, with limited Q2 upside. We believe price increases were likely already embedded in guidance. We remain Neutral-rated, though our PT lowers to $275 (from $295) implying ~17x FY27 FCF with limited estimate changes and a slightly higher valuation discount for increased competition.” Barclays: Overweight, $316 The financial institution’s projection of the place the inventory ought to commerce in a 12 months represents 23% upside. “We are not sure Q2 will be a major catalyst for CRM. The quarter itself was slightly better, but the guidance was slightly weaker despite more positive macro comments (especially in SMB). Agentforce seems to be seeing more adoption but numbers remain small and hence, investors need to be patient.” Bank of America: Buy, $325 Bank of America’s worth goal is 27% above Salesforce’s Wednesday closing worth. “The outlook for Q3 cRPO growth of 10% suggests that low double digit growth is intact, with potential for a reacceleration in FY27 from added AI contribution. We are encouraged by a raised outlook for FY26 FCF growth 3% points to 12% to 13%. This backs our view that Salesforce is on track to deliver sustained mid teens FCF growth, before material contribution from Agentforce. With added traction, we see potential for a reset to solid high teens FCF growth.” Deutsche Bank: Buy, $340 Analyst Brad Zelnick sees shares rising 33% from right here. “Salesforce reported F2Q results that were generally in line with muted investor expectations. Solid underlying trends continued, with headline metrics (cRPO, revenue, margins) modestly ahead of consensus … While continued strength in Data Cloud/AI was evident once again with stable 120% y/y growth, we believe the seemingly intensive implementation process is limiting near-term contribution. While more meaningful monetization remains on the horizon, we were encouraged to see paid closed deals accelerate (with 2K new paid in the quarter vs 1K in F1Q), aligning with management’s focus on optimizing for usage.” JPMorgan: Overweight, $365 JPMorgan’s worth goal is roughly 42% above the place shares of Salesforce closed on Wednesday. “Salesforce continues to emphasize the momentum it is seeing across its AI solutions while simultaneously hinting at improving pipeline and bookings trends as well as offering constructive commentary on growth potential over the intermediate term — comments that, in our view, are somehow falling on deaf ears due to overdone concerns relating to the potential impact of AI on seat-based SaaS models. While we understand that growth has not inflected yet and investors are thus not seeing an imminent need to revise their thought process, our view is that Q2 results and positive company commentary are sufficient at this juncture, considering CRM shares are trading near a historically low valuation level and deep discount to software peers.” Goldman Sachs: Buy, $385 The financial institution’s 12-month worth forecast implies upside of fifty%. “Contrary to prevailing investor concerns, we don’t believe AI will disrupt Salesforce’s SaaS business but instead become a multi-year tailwind … While results on the surface appeared modestly ahead across most important metrics, the weakness in the stock can be tied to a lack of meaningful reacceleration implied in F2H26 guidance. That said, we remain constructive.” Morgan Stanley: Overweight, $405 Morgan Stanley’s worth goal is roughly 72% above the place shares of Salesforce are buying and selling Thursday. “While Q2 results fell largely inline with expectations, the pieces are coming together for an improving growth trajectory – building traction in Agentforce/Data Cloud, ramping sales capacity and accelerating pipeline growth. At 16X EV/CY26 FCF, we would be building positions ahead of this turn.”